0
Gilead Sciences Inc has said that it has started an early-stage study of its antiviral Covid-19 treatment remdesivir that can be inhaled, for use outside of hospitals.
The company said the trial, which will enroll about 60 healthy Americans aged between 18 and 45, will test the drug particularly in those cases where the disease has not progressed to require hospitalisation.
